Cookie Policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read ourPrivacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

CENTURY II Trial highlights

01/10/2015 -  

Multicentre, intercontinental study - 58 sites in 13 countries across Europe, Japan, and South Korea - Primary endpoint: Freedom from TLF at 9 months - Secondary endpoint: rate of TVF; patient-oriented composite endpoint; rate of TLR, TVR, ST, cardiac death, MI; composite of cardiac death and MI; rate of bleeding and vascular complications - Clinical follow-up up to 5 years

Study design and key features

 


 "Xience" is a product and trademark of the Abbott Group of Companies

Ultimaster was non-inferior to Xience in terms of the primary endpoint: freedom from TLF at 9 months

 

Saito S et al. Eur Heart J 2014;35:2021–31.


 

CENTURY II included pre-specified assessment of complex subgroups

 


 

CENTURY II Bifurcation lesions. Target Lesion Failure at 24 months

 

B. Merkely et al. Treatment of bifurcation lesions with a thin-strut DES with bioresorbable polymer – clinical outcomes of the CENTURY II trial. Presented at EuroPCR 2015.
Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Interv. 2015 Aug 13. doi: 10.1002/ccd.26150.


 

CENTURY II Bifurcation lesions. Clinical outcomes at 24 months

 

B. Merkely et al. Treatment of bifurcation lesions with a thin-strut DES with bioresorbable polymer – clinical outcomes of the CENTURY II trial. Presented at EuroPCR 2015.
Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Interv. 2015 Aug 13. doi: 10.1002/ccd.26150.